Drug discovery notoriously suffers from high attrition rates during clinical trials. A major contributing factor to this issue is the frequent failure to identify adverse neural functional effects of compounds in the CNS at earlier stages of drug development than currently possible. To address this unmet need, the (side-)effects of the widely used antitussive dextromethorphan were assessed...